- call +1-201-465-4211
- email sales@mrinsights.biz
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease and motor neuron disease (MND), is a neurodegenerative disease, affecting nerve cells in the brain and spinal cord that controls voluntary muscles. The disease is progressive in nature, meaning it gets worse over time.
Scope of the Report:
North America is expected to hold a dominant position in the amyotrophic lateral sclerosis treatment market, as major companies present in the region are focusing on collaborations for product development.
The global Amyotrophic Lateral Sclerosis (ALS) Treatment market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Amyotrophic Lateral Sclerosis (ALS) Treatment.
Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.
This report studies the Amyotrophic Lateral Sclerosis (ALS) Treatment market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Amyotrophic Lateral Sclerosis (ALS) Treatment market by product type and applications/end industries.
Market Segment by Companies, this report covers
Mitsubishi Tanabe Pharma
Takeda Pharmaceutical
Sanofi
Johnson & Johnson
Mylan Pharmaceuticals
Janssen Pharmaceutical
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Riluzole
Edaravone (Radicava)
Others
Market Segment by Applications, can be divided into
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Amyotrophic Lateral Sclerosis (ALS) Treatment Market Overview
1.1 Product Overview and Scope of Amyotrophic Lateral Sclerosis (ALS) Treatment
1.2 Classification of Amyotrophic Lateral Sclerosis (ALS) Treatment by Types
1.2.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Comparison by Types (2017-2023)
1.2.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Market Share by Types in 2017
1.2.3 Riluzole
1.2.4 Edaravone (Radicava)
1.2.5 Others
1.3 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Application
1.3.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Market Share Comparison by Applications (2013-2023)
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Regions
1.4.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size (Million USD) Comparison by Regions (2013-2023)
1.4.1 North America (USA, Canada and Mexico) Amyotrophic Lateral Sclerosis (ALS) Treatment Status and Prospect (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy) Amyotrophic Lateral Sclerosis (ALS) Treatment Status and Prospect (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Amyotrophic Lateral Sclerosis (ALS) Treatment Status and Prospect (2013-2023)
1.4.4 South America (Brazil, Argentina, Colombia) Amyotrophic Lateral Sclerosis (ALS) Treatment Status and Prospect (2013-2023)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Amyotrophic Lateral Sclerosis (ALS) Treatment Status and Prospect (2013-2023)
1.5 Global Market Size of Amyotrophic Lateral Sclerosis (ALS) Treatment (2013-2023)
2 Manufacturers Profiles
2.1 Mitsubishi Tanabe Pharma
2.1.1 Business Overview
2.1.2 Amyotrophic Lateral Sclerosis (ALS) Treatment Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue, Gross Margin and Market Share (2016-2017)
2.2 Takeda Pharmaceutical
2.2.1 Business Overview
2.2.2 Amyotrophic Lateral Sclerosis (ALS) Treatment Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Takeda Pharmaceutical Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue, Gross Margin and Market Share (2016-2017)
2.3 Sanofi
2.3.1 Business Overview
2.3.2 Amyotrophic Lateral Sclerosis (ALS) Treatment Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Sanofi Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue, Gross Margin and Market Share (2016-2017)
2.4 Johnson & Johnson
2.4.1 Business Overview
2.4.2 Amyotrophic Lateral Sclerosis (ALS) Treatment Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Johnson & Johnson Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue, Gross Margin and Market Share (2016-2017)
2.5 Mylan Pharmaceuticals
2.5.1 Business Overview
2.5.2 Amyotrophic Lateral Sclerosis (ALS) Treatment Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Mylan Pharmaceuticals Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue, Gross Margin and Market Share (2016-2017)
2.6 Janssen Pharmaceutical
2.6.1 Business Overview
2.6.2 Amyotrophic Lateral Sclerosis (ALS) Treatment Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Janssen Pharmaceutical Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue, Gross Margin and Market Share (2016-2017)
3 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Competition, by Players
3.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Share by Players (2013-2018)
3.2 Market Concentration Rate
3.2.1 Top 5 Amyotrophic Lateral Sclerosis (ALS) Treatment Players Market Share
3.2.2 Top 10 Amyotrophic Lateral Sclerosis (ALS) Treatment Players Market Share
3.3 Market Competition Trend
4 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Regions
4.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Market Share by Regions
4.2 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Growth Rate (2013-2018)
4.3 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Growth Rate (2013-2018)
4.4 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Growth Rate (2013-2018)
4.5 South America Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Growth Rate (2013-2018)
4.6 Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Growth Rate (2013-2018)
5 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Countries
5.1 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Countries (2013-2018)
5.2 USA Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Growth Rate (2013-2018)
5.3 Canada Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Growth Rate (2013-2018)
5.4 Mexico Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Growth Rate (2013-2018)
6 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Countries
6.1 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Countries (2013-2018)
6.2 Germany Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Growth Rate (2013-2018)
6.3 UK Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Growth Rate (2013-2018)
6.4 France Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Growth Rate (2013-2018)
6.5 Russia Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Growth Rate (2013-2018)
6.6 Italy Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Growth Rate (2013-2018)
7 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Countries
7.1 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Countries (2013-2018)
7.2 China Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Growth Rate (2013-2018)
7.3 Japan Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Growth Rate (2013-2018)
7.4 Korea Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Growth Rate (2013-2018)
7.5 India Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Growth Rate (2013-2018)
7.6 Southeast Asia Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Growth Rate (2013-2018)
8 South America Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Countries
8.1 South America Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Countries (2013-2018)
8.2 Brazil Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Growth Rate (2013-2018)
8.3 Argentina Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Growth Rate (2013-2018)
8.4 Colombia Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Growth Rate (2013-2018)
9 Middle East and Africa Revenue Amyotrophic Lateral Sclerosis (ALS) Treatment by Countries
9.1 Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Countries (2013-2018)
9.2 Saudi Arabia Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Growth Rate (2013-2018)
9.3 UAE Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Growth Rate (2013-2018)
9.4 Egypt Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Growth Rate (2013-2018)
9.5 Nigeria Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Growth Rate (2013-2018)
9.6 South Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Growth Rate (2013-2018)
10 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Segment by Type
10.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Market Share by Type (2013-2018)
10.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Forecast by Type (2018-2023)
10.3 Riluzole Revenue Growth Rate (2013-2023)
10.4 Edaravone (Radicava) Revenue Growth Rate (2013-2023)
10.5 Others Revenue Growth Rate (2013-2023)
11 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Segment by Application
11.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Market Share by Application (2013-2018)
11.2 Amyotrophic Lateral Sclerosis (ALS) Treatment Market Forecast by Application (2018-2023)
11.3 Hospital Pharmacies Revenue Growth (2013-2018)
11.4 Retail Pharmacies Revenue Growth (2013-2018)
11.5 Online Pharmacies Revenue Growth (2013-2018)
12 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Forecast (2018-2023)
12.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Forecast (2018-2023)
12.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Forecast by Regions (2018-2023)
12.3 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Market Forecast (2018-2023)
12.4 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Market Forecast (2018-2023)
12.5 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Market Forecast (2018-2023)
12.6 South America Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Market Forecast (2018-2023)
12.7 Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Market Forecast (2018-2023)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
List of Tables and Figures
Figure Amyotrophic Lateral Sclerosis (ALS) Treatment Picture
Table Product Specifications of Amyotrophic Lateral Sclerosis (ALS) Treatment
Table Global Amyotrophic Lateral
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
